17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and ...
6 April 2023 - Ground breaking commercial deals for the anti-cancer medicine olaparib have paved the way for hundreds to benefit ...
6 April 2023 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...
5 April 2023 - Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group ...
29 March 2023 - It is estimated that around 400 people with advanced cervical cancer will be eligible for pembrolizumab ...
22 March 2023 - NICE has published evidence based recommendations on the use of nivolumab (Opdivo) in combination with chemotherapy ...
28 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access ...
27 February 2023 - Dr Asha Umrawsingh, 50, was first diagnosed with breast cancer in 2010. ...
22 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
22 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement ...
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who ...
8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option ...